Memory Impairment Screening Tool Gains FDA Clearance

Wednesday, January 25, 2017

The FDA has granted 510(k) clearance to CANTAB Mobile (Cambridge Cognition), a sensitive screening tool for the detection clinically-relevant memory impairment in older adults at the point of care. CANTAB Mobile includes a computerized test of visuospatial associative learning (CANTAB PAL) to assess episodic memory with optional mood and functional assessments, which can help to detect symptoms of depression and problems with performing regular activities of daily living. The touchscreen test, which takes under 10 minutes to complete, can be self-administered using voiceover instructions in over 20 languages with automatic scoring, accounting for age, gender and education level. All results can be accessed in a simple to interpret, one-page physician's report using a traffic-light output for memory and mood outputs.  

Next Story


You must be logged in to leave a comment.